In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Nordic Myeloma Study Group; Thomas Lund; Michael Tveden Gundesen; Annette Juul Vangsted; Carsten Helleberg; Einar Haukås; Trine Silkjær; Jon Thor Asmussen; Elena Manuela Teodorescu; Bo Amdi Jensen; Tobias Schmidt Slørdahl; Hareth Nahi; Anders Waage; Niels Abildgaard; Fredrik Schjesvold

doi:10.1038/s41408-024-01046-2

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Nordic Myeloma Study Group, Thomas Lund^*, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold

^*Corresponding author af dette arbejde

Hæmatologisk Afdeling

Publikation: Bidrag til tidsskrift › Letter › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	65
Antal sider	5
Tidsskrift	Blood cancer journal
Vol/bind	14
Udgave nummer	1
DOI	https://doi.org/10.1038/s41408-024-01046-2
Status	Udgivet - 15 apr. 2024

Adgang til dokumentet

10.1038/s41408-024-01046-2

Citationsformater

Nordic Myeloma Study Group, Lund, T., Gundesen, M. T., Juul Vangsted, A., Helleberg, C., Haukås, E., Silkjær, T., Asmussen, J. T., Manuela Teodorescu, E., Amdi Jensen, B., Schmidt Slørdahl, T., Nahi, H., Waage, A., Abildgaard, N., & Schjesvold, F. (2024). In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal, 14(1), Artikel 65. https://doi.org/10.1038/s41408-024-01046-2

@article{8f39ee5260904295ad87d5e4e3d629b4,

title = "In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease",

author = "{Nordic Myeloma Study Group} and Thomas Lund and Gundesen, {Michael Tveden} and {Juul Vangsted}, Annette and Carsten Helleberg and Einar Hauk{\aa}s and Trine Silkj{\ae}r and Asmussen, {Jon Thor} and {Manuela Teodorescu}, Elena and {Amdi Jensen}, Bo and {Schmidt Sl{\o}rdahl}, Tobias and Hareth Nahi and Anders Waage and Niels Abildgaard and Fredrik Schjesvold",

year = "2024",

month = apr,

day = "15",

doi = "10.1038/s41408-024-01046-2",

language = "English",

volume = "14",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

Nordic Myeloma Study Group, Lund, T, Gundesen, MT, Juul Vangsted, A, Helleberg, C, Haukås, E, Silkjær, T, Asmussen, JT, Manuela Teodorescu, E, Amdi Jensen, B, Schmidt Slørdahl, T, Nahi, H, Waage, A, Abildgaard, N & Schjesvold, F 2024, 'In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease', Blood cancer journal, bind 14, nr. 1, 65. https://doi.org/10.1038/s41408-024-01046-2

TY - JOUR

T1 - In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

AU - Nordic Myeloma Study Group

AU - Lund, Thomas

AU - Gundesen, Michael Tveden

AU - Juul Vangsted, Annette

AU - Helleberg, Carsten

AU - Haukås, Einar

AU - Silkjær, Trine

AU - Asmussen, Jon Thor

AU - Manuela Teodorescu, Elena

AU - Amdi Jensen, Bo

AU - Schmidt Slørdahl, Tobias

AU - Nahi, Hareth

AU - Waage, Anders

AU - Abildgaard, Niels

AU - Schjesvold, Fredrik

PY - 2024/4/15

Y1 - 2024/4/15

U2 - 10.1038/s41408-024-01046-2

DO - 10.1038/s41408-024-01046-2

M3 - Letter

C2 - 38622134

SN - 2044-5385

VL - 14

JO - Blood cancer journal

JF - Blood cancer journal

IS - 1

M1 - 65

ER -